Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSCI NASDAQ:DARE NASDAQ:LIAN NASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSCICOSCIENS Biopharma$2.72$3.01$2.50▼$4.40$8.64M0.917,571 shsN/ADAREDare Bioscience$1.88-13.8%$2.23$1.27▼$9.19$28.16M1.07437,456 shs450,663 shsLIANLianBio$0.16+15.0%$0.13$0.27▼$4.99$17.28M0.231.04 million shs1,698 shsTVGNTevogen Bio$10.47+6.2%$7.24$4.14▼$75.50$43.60M0.1438,592 shs100,552 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSCICOSCIENS Biopharma0.00%0.00%0.00%0.00%-26.88%DAREDare Bioscience-13.76%-15.70%-40.51%+22.88%-39.35%LIANLianBio-15.71%+26.13%-0.71%+52.75%-63.32%TVGNTevogen Bio+6.19%+32.36%+48.09%+43.23%-83.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSCICOSCIENS Biopharma$2.72$3.01$2.50▼$4.40$8.64M0.917,571 shsN/ADAREDare Bioscience$1.88-13.8%$2.23$1.27▼$9.19$28.16M1.07437,456 shs450,663 shsLIANLianBio$0.16+15.0%$0.13$0.27▼$4.99$17.28M0.231.04 million shs1,698 shsTVGNTevogen Bio$10.47+6.2%$7.24$4.14▼$75.50$43.60M0.1438,592 shs100,552 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSCICOSCIENS Biopharma0.00%0.00%0.00%0.00%-26.88%DAREDare Bioscience-13.76%-15.70%-40.51%+22.88%-39.35%LIANLianBio-15.71%+26.13%-0.71%+52.75%-63.32%TVGNTevogen Bio+6.19%+32.36%+48.09%+43.23%-83.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSCICOSCIENS Biopharma 0.00N/AN/AN/ADAREDare Bioscience 2.33Hold$10.00431.91% UpsideLIANLianBio 0.00N/AN/AN/ATVGNTevogen Bio 1.50Reduce$100.00855.11% UpsideCurrent Analyst Ratings BreakdownLatest CSCI, LIAN, DARE, and TVGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026DAREDare Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026TVGNTevogen Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSCICOSCIENS Biopharma$9.44M0.91N/AN/A$3.49 per share0.78DAREDare Bioscience$1.03M27.34N/AN/A$0.20 per share9.40LIANLianBioN/AN/AN/AN/A$2.71 per shareN/ATVGNTevogen BioN/AN/AN/AN/A($211.84) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSCICOSCIENS Biopharma-$15.31M-$6.01N/AN/AN/A-199.55%-149.49%-54.80%N/ADAREDare Bioscience-$13.40M-$0.95N/AN/AN/AN/AN/A-46.22%8/13/2026 (Estimated)LIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/ATVGNTevogen Bio-$26.27M-$4.61N/AN/AN/AN/AN/A-472.77%8/13/2026 (Estimated)Latest CSCI, LIAN, DARE, and TVGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026TVGNTevogen Bio-$2.64-$1.61+$1.03-$1.61N/AN/A5/14/2026Q1 2026DAREDare Bioscience-$0.33-$0.20+$0.13-$0.21$0.03 million$0.15 million3/26/2026Q4 2025DAREDare Bioscience-$0.44-$0.02+$0.42-$0.02$0.75 million$1.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCSCICOSCIENS BiopharmaN/AN/AN/AN/AN/ADAREDare BioscienceN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSCICOSCIENS BiopharmaN/A2.982.65DAREDare BioscienceN/A1.031.03LIANLianBioN/A10.0610.06TVGNTevogen BioN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSCICOSCIENS Biopharma0.73%DAREDare Bioscience6.70%LIANLianBio74.85%TVGNTevogen BioN/AInsider OwnershipCompanyInsider OwnershipCSCICOSCIENS Biopharma0.10%DAREDare Bioscience4.10%LIANLianBio7.59%TVGNTevogen Bio70.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSCICOSCIENS Biopharma203.18 million3.17 millionN/ADAREDare Bioscience3014.98 million14.37 millionNot OptionableLIANLianBio110108.06 million99.86 millionNot OptionableTVGNTevogen Bio34.16 million1.23 millionN/ACSCI, LIAN, DARE, and TVGN HeadlinesRecent News About These CompaniesTevogen Bio (NASDAQ:TVGN) Trading 6.2% Higher - Should You Buy?June 6 at 2:55 AM | americanbankingnews.comTevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual RevenueMay 28, 2026 | finanznachrichten.deTevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 ...May 28, 2026 | enidnews.comETevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual RevenueMay 28, 2026 | globenewswire.comTevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services ...May 21, 2026 | caledonianrecord.comCTevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Strategic Healthcare TransactionMay 21, 2026 | quiverquant.comQTevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services OrganizationMay 21, 2026 | globenewswire.comTevogen Bio Holdings Inc. Reports Significant Operational Improvements and Strategic Growth InitiativesMay 18, 2026 | quiverquant.comQLetter to Shareholders from CEO Dr. Ryan SaadiMay 18, 2026 | globenewswire.comTevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest ...May 12, 2026 | caledonianrecord.comCTevogen Bio Holdings Inc. Secures $3 Million PIPE Financing from The Patel Family, LLPMay 12, 2026 | quiverquant.comQTevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market CloseMay 12, 2026 | globenewswire.comTevogen (TVGN) Soars 11% as Firm Gears Up for AI Training CommercializationMay 5, 2026 | finance.yahoo.comTevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application PortalApril 27, 2026 | finance.yahoo.comTevogen.AI Nears Completion of PredicTcellâ„¢ Training; Initiates Commercial Readiness and Debuts Internal Application PortalApril 27, 2026 | globenewswire.comTevogen Bio krijgt melding van Nasdaq wegens niet-naleving beursregelsApril 23, 2026 | nl.investing.comTevogen Bio Faces Nasdaq Market Value Compliance ChallengesApril 22, 2026 | tipranks.comTevogen Bio Holdings (TVGN) price target increased by 1,900.00% to 102.00March 27, 2026 | msn.comTevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and ...March 26, 2026 | caledonianrecord.comCTevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue GrowthMarch 26, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026TMC Forges a New EV Supply Chain at the Bottom of the SeaBy Jeffrey Neal Johnson | May 12, 2026GitLab’s Price Recovery Gains Traction—Time to Get On Board?By Thomas Hughes | June 4, 2026Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?By Jessica Mitacek | May 28, 2026CSCI, LIAN, DARE, and TVGN Company DescriptionsCOSCIENS Biopharma NASDAQ:CSCICOSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Dare Bioscience NASDAQ:DARE$1.88 -0.30 (-13.76%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.95 +0.07 (+3.72%) As of 06/5/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.LianBio NASDAQ:LIAN$0.16 +0.02 (+15.04%) As of 06/5/2026LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Tevogen Bio NASDAQ:TVGN$10.47 +0.61 (+6.19%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$10.26 -0.21 (-2.00%) As of 06/5/2026 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
